INM 901
Alternative Names: INM-901Latest Information Update: 07 Aug 2024
At a glance
- Originator InMed Pharmaceuticals
- Class Antidementias; Cannabinoids; Neuroprotectants
- Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists; Peroxisome proliferator-activated receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 30 Jul 2024 Pharmacodynamics data from preclinical studies in Alzheimer's disease released by InMed Pharmaceuticals
- 04 Apr 2024 Pharmacodynamics data from preclinical studies in Alzheimer's disease released by InMed Pharmaceuticals
- 24 Oct 2023 Preclinical trials in Alzheimer's disease in Canada (unspecified route)